Keyphrases
T Cell Receptor
89%
Allogeneic Blood or Marrow Transplantation
60%
Post-transplantation Cyclophosphamide (PTCy)
56%
Bispecific Antibody
45%
Confidence Interval
43%
T Cells
37%
BCL10
35%
Effector T Cells
31%
Cancer Cells
30%
Chimeric Antigen Receptor T Cells (CAR-T)
29%
Overall Survival
29%
Neoantigen
29%
NF-B
29%
T Cell Receptor Signaling
27%
Nuclear factor-B
27%
Peripheral T-cell Lymphoma
27%
Allogeneic Transplantation
27%
Checkpoint Inhibition
27%
Immune Checkpoint Inhibitors
27%
TRBC1
27%
Antibody-drug Conjugate
27%
Graft-versus-host Disease (GvHD)
25%
T Cell Activation
22%
Nonmyeloablative
19%
Receptor Targets
19%
Antibody Therapy
18%
Signalosome
17%
Relapsed or Refractory
17%
New Human Leukocyte Antigen Allele
17%
Mouse Model
16%
Antibody Targeting
16%
MALT1
16%
Immunological Synapse
16%
Improved Outcomes
16%
Nuclear factor-κB
15%
Tumor
15%
Classic Hodgkin Lymphoma
14%
Electroretinogram
13%
Acute Lymphoblastic Leukemia
13%
Checkpoint Blockade
13%
Continuous Veno-venous Hemodialysis
13%
Checkpoint Blockade Therapy
13%
Chronic Lymphocytic Leukemia
13%
Specific Immunotherapy
13%
Ubiquitination
13%
Blood or Marrow Transplantation
13%
High Dose
13%
Subsequent Therapy
13%
Shock
13%
Vigabatrin
13%
Immunology and Microbiology
T Cell Receptor
100%
T Cell
69%
Neoantigen
57%
Overall Survival
50%
Bispecific Antibody
46%
Cancer Cell
46%
Cyclophosphamide
45%
Progression Free Survival
37%
Graft-Versus-Host Disease
29%
Chimeric Antigen Receptor
28%
Allele
23%
Human Leukocyte Antigen
20%
Transplant Procedure
20%
Conditioning
20%
Mouse
19%
Immunotherapy
19%
Monospecific Antibody
16%
Immunological Synapse
16%
P53
15%
Immunoglobulin Enhancer Binding Protein
13%
Selective Autophagy
13%
Allotransplantation
13%
Drug Megadose
13%
Immune Checkpoint Blockade
13%
Recurrence Free Survival
13%
Cell Clone
13%
Heterozygosity
13%
Complement Factor B
13%
Preclinical Study
13%
Acute Graft Versus Host Disease
13%
Allograft
13%
Antibody Drug Conjugate
13%
Rituximab
13%
Chronic Graft Versus Host Disease
12%
Cell Surface
11%
Immunosuppression
11%
Receptor Type Tyrosine Protein Phosphatase C
10%
Therapeutic Antibodies
8%
Infectious Agent
8%
Autophagy
7%
Wild Type
7%
Signal Transduction
7%
Chimeric Antigen Receptor T-Cell Therapy
6%
Sensitization
6%
B Cell
6%
Engraftment
6%
T Cell Proliferation
5%
Morbidity
5%
Gene Mutation
5%
Cell Differentiation
5%
Medicine and Dentistry
T Lymphocyte Receptor
43%
T Cell
42%
Cyclophosphamide
42%
Malignant Neoplasm
42%
Peripheral T-Cell Lymphoma
27%
Hodgkin's Lymphoma
27%
Overall Survival
27%
Bispecific Antibody
22%
Cancer Cell
17%
Graft Versus Host Reaction
16%
Allograft
15%
Chimeric Antigen Receptor
15%
Flow Cytometry
13%
Nuclear Factor
13%
English (Language)
13%
Ciclonicate
13%
Vigabatrin
13%
Shock (Circulatory)
13%
Drug Megadose
13%
Cancer Therapy
13%
B-Cell Chronic Lymphocytic Leukemia
13%
Acute Lymphoblastic Leukemia
13%
Immunoassay
13%
Immune Checkpoint Inhibitor
13%
Visual Dysfunction
13%
Immune Checkpoint Blockade
13%
Alternative Complement Pathway C3 C5 Convertase
13%
Cutaneous T Cell Lymphoma
13%
Epileptic Seizure
13%
Chimeric Antigen Receptor T-Cell
11%
Progression Free Survival
11%
Mycosis fungoides
9%
Sezary Syndrome
9%
Clonal Variation
9%
Disease
8%
Hazard Ratio
8%
T-Cell Lymphoma
8%
Whole Body Radiation
7%
Recurrence Free Survival
7%
Acute Graft Versus Host Disease
7%
Targeted Therapy
7%
Cytotechnology
6%
B-Cell Lymphoma
6%
Chimeric Antigen Receptor T-Cell Immunotherapy
6%
Hope
6%
Diseases
6%
Monoclonal Antibody
6%
Immunotherapy
6%
Cumulative Incidence
6%
Prophylaxis
5%
